Results 61 to 70 of about 447,312 (181)

Association Between the GMI/HbA1c Ratio and Microvascular Complications in Type 1 Diabetes: A Multicenter Cross‐Sectional Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective To clarify whether the glucose management indicator (GMI)/glycated haemoglobin (HbA1c) ratio (GMI/HbA1c ratio) is an independent predictor of microvascular complications in Type 1 diabetes (T1D). Design and Methods Multicentre, cross‐sectional, observational study including subjects with T1D with at least 5 years of evolution, users ...
Sandra Herranz‐Antolín, María Asunción Martínez‐Brocca, Gloria Cánovas‐Molina, Aurora Aragón‐Alonso, Miguel Brito‐Sanfiel, Jose Ignacio Martínez‐Montoro, Virginia Bellido, Sharona Azriel, María del Carmen López‐García, Cristina Tejera, Amparo Bartual, Verónica Perea, Pedro José Pines, Antonio J. Amor, Óscar Moreno‐Pérez, Rebeca Reyes‐García, Gema López‐Gallardo, María Durán‐Martínez, Cristina Serrano, Rosa Márquez‐Pardo, Noemí González‐Pérez de Villar, Manuel Gargallo, Estefanía Santos, Pedro Pujante, Jessica Ares, Diego Bellido, Ignacio Conget, Fernando Gomez‐Peralta   +27 more
wiley   +1 more source

Kidney Outcomes With GLP‐1 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real‐World Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To compare kidney outcomes after GLP‐1 receptor agonists (RA) or tirzepatide (GLP‐1/GIP RAs) versus finerenone initiation in adults with Type 2 diabetes (T2D) and moderate chronic kidney disease (CKD). Methods In a retrospective TriNetX global network study (July 2021–November 2025), adults with T2D and CKD stages 3–4 initiating GLP‐1/GIP ...
Dvora R. Sehtman‐Shachar, Alisa Fishkin, Gil Leibowitz, Ofri Mosenzon, Meir Schechter, Genya Aharon‐Hananel   +5 more
wiley   +1 more source

TREATMENT OF DIABETIC DISTAL POLYNEUROPATHY WITH ACTOVEGIN® IN TYPE 2 DIABETIC PATIENTS.

Медицинский совет, 2017
The possibilities of treatment of diabetic polyneuropathy with Actovegin® are discussed in this publication.  In the multicenter, randomized, double-blind trial 567  patients  with type 2  diabetes  received 20  intravenous infusions of 20% solution  of ...
E. U. Komelyagina, M. B. Antsiferov
doaj   +1 more source

Diabetic Distal Symmetrical Polyneuropathy: Correlation of Clinical, Laboratory, and Electrophysiologic Studies in Patients with Type 2 Diabetes Mellitus

Journal of Diabetes Research, 2020
This cross-sectional study is aimed at determining the prevalence of distal symmetrical polyneuropathy (DSPN) and diabetic peripheral neuropathic pain (DPNP) in participants with type 2 diabetes mellitus (T2DM); finding the risk factors for DSPN and DPNP
Yi-Ching Weng, Sung-Sheng Tsai, Rong-Kuo Lyu, Chun-Che Chu, Long-Sun Ro, Ming-Feng Liao, Hong-Shiu Chang, Chiung-Mei Chen, Jawl-Shan Hwang, Hung-Chou Kuo   +9 more
doaj   +1 more source

Prevalence and Disability of Peripheral Neuropathy in Patients With Waldenström's Macroglobulinemia

European Journal of Haematology, EarlyView.
ABSTRACT Objectives Peripheral neuropathy (PN) is considered a frequent complication of Waldenström's macroglobulinemia (WM). Establishing a causal relationship between PN and WM is complicated by confounding factors such as age‐related axonal loss and diabetes. This scoping review aims to summarize the current evidence on WM‐associated PN with a focus
Morten Müller Aagaard, Kristoffer Nagy Skaastrup, Louise Sloth Kodal, Britt Stævnsbo Pedersen, Troels Hammer, John Vissing, Tina Dysgaard   +6 more
wiley   +1 more source

Ranirestat Improved Nerve Conduction Velocities, Sensory Perception, and Intraepidermal Nerve Fiber Density in Rats with Overt Diabetic Polyneuropathy

Journal of Diabetes Research, 2019
Distal sensory-motor polyneuropathy is one of the most frequent diabetic complications. However, few therapies address the etiology of neurodegeneration in the peripheral nervous systems of diabetic patients.
Saeko Asano, Tatsuhito Himeno, Tomohide Hayami, Mikio Motegi, Rieko Inoue, Hiromi Nakai-Shimoda, Emiri Miura-Yura, Yoshiaki Morishita, Masaki Kondo, Shin Tsunekawa, Yoshiro Kato, Koichi Kato, Keiko Naruse, Jiro Nakamura, Hideki Kamiya   +14 more
doaj   +1 more source

ACTOVEGIN® IN THERAPY OF SUBCLINICAL DISTAL SYMMETRICAL SENSOR-MOTOR POLYNEUROPATHY IN 2ND TYPE DIABETES MELLITUS

Медицинский совет, 2016
A study of 103 2nd diabetes mellitus inpatients was carried out with the help of the composite test (clinical scales TSS and NIS LL + 7 EMG-characteristics of the leg peripheral nerves’ state) for diagnosing and establishing stages of diabetic ...
A. S. FOKINA, I. A. STROKOV, А. V. ZILOV   +2 more
doaj   +1 more source

Vitamin B6: too much, too little, too late? An analysis of sales trends in Australia from 2023 to 2025

Internal Medicine Journal, EarlyView.
Abstract Background Peripheral neuropathy associated with vitamin B6 (pyridoxine) is dose and duration dependent. High‐dose vitamin B6 products associated with adverse neurological effects are available in Australia, prompting recent regulatory action to reschedule products containing ≥50 mg pyridoxine to schedule 3 (pharmacist only).
Wai‐Jo Jocelin Chan, Jennifer Hunter, Vivian Yeukman Lee, Rose Cairns, Slade Mathews, Joanna E. Harnett   +5 more
wiley   +1 more source

Painful Diabetic Polyneuropathy

, 2011
In the industrialized world, polyneuropathy induced by diabetes mellitus (DM) is one of the most prevalent forms of neuropathy. Diabetic neuropathy can result from a direct toxic effect of glucose on nerve cells.
Pluijms, Wouter, Huygen, Frank; id_orcid, Frank Huygen, Maarten van Kleef, Van Zundert, Jan, Jan Van Zundert, Cheng, Jianguo, Nagy Mekhail, Robert van Dongen, van Kleef, Maarten, Jianguo Cheng, Mekhail, Nagy, van Dongen, Robert, Wouter Pluijms   +13 more
core   +1 more source

The low fasting serum C‐peptide level was associated with reduced sural nerve action potential amplitudes: A cross‐sectional study of Japanese type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
Low fasting serum C‐peptide levels were independently associated with abnormal sural nerve action potential amplitude measured by DPNCheck® in patients with type 2 diabetes. Fasting serum C‐peptide may serve as a clinically relevant marker for diabetic polyneuropathy. ABSTRACT Aims/Introduction The association between the fasting serum C‐peptide levels
Taichi Muramatsu, Kaori Inoue‐Yamamoto, Daisuke Yamamuro, Akifumi Kushiyama   +3 more
wiley   +1 more source